FDA Generic Drug User Fee Rates: Fiscal Year 2016

August 7, 2015

As required by the Generic Drug User Fee Amendments of 2012, FDA has announced the 2016 rates for the following user fees:

  • Abbreviated new drug application (ANDA),
  • Prior approval to an ANDA (PAS),
  • Type II active pharmaceutical ingredient drug master file (DMF),
  • Generic drug active pharmaceutical ingredient (API) facilities, and
  • Finished dosage form (FDF) facilities.

These fees are collected to ensure FDA has the needed funds to employ the staff needed to review drugs in a timely manner, thus getting drugs approved and to market in a more efficient time frame. The rates are amended annually and are effective each fiscal year, from October 1 to September 30.

The generic drug user fee rates for fiscal year 2016 are as follows:

Applications:

Fee Category

Fee Rates for FY 2016
Abbreviated New Drug Application (ANDA)

$76, 030
Prior Approval Supplement (PAS) to ANDA

$38,020
Drug Master File (DMF)

$42,170

 

Facilities:

Fee Category

Fee Rates for FY 2016
Active Pharmaceutical Ingredient (API) - Domestic

$40,867
API – Foreign

$55,867
Finished Dosage Form (FDF) – Domestic

$243,905
FDF – Foreign

$258,905

 

Need help deciding which application is right for your generic product? We can help you get through FDA successfully in a more time and cost efficient manner. To learn more about how we can help, please contact us. 

TAGS: Agency Alerts

Related Articles

Generic Drugs

August 4, 2016

FDA Generic Drug User Fee Rates: Fiscal Year 2017

FDA has announced its 2017 user fee rates related to the Generic Drug User Fee Program, which includes: Abbreviated new drug applications (ANDAs) Prior approval supplements (PASs) to an approved ANDA...

Continue reading the blog post
Agency Alerts

August 7, 2018

FDA Generic Drug User Fee Rates: Fiscal Year 2019

On Friday, July 27th, FDA released a notice with updated generic drug user fee rates for fiscal year 2019. Under GDUFA II, user fees should total $493,600,000 each year, adjusted for inflation. The...

Continue reading the blog post
Regulatory Sciences

April 7, 2021

Understanding FDA Pre-ANDA Meetings

Brought into being by the Generic Drug User Fee Amendments Reauthorization of 2017 (GDUFA II), the FDA’s pre-ANDA program is designed to accelerate access to generic versions of complex products. The...

Continue reading the blog post